Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway

Cancer Letters

Volumn 277, Issue 1, 2009, Pages 72-81

  Ketterer, Knut ^a   Kong, Bo ^a   Frank, Dietwalt ^b   Giese, Nathalia A ^b   Bauer, Andrea ^c   Hoheisel, Jörg ^c   Korc, Murray ^d   Kleeff, Jörg ^a   Michalski, Christoph W ^a   Friess, Helmut ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

c Met; Metastasis; Neuromedin U; Neuromedin U receptor; Pancreatic cancer

Indexed keywords

NEUROMEDIN U; NEUROMEDIN U RECEPTOR 2; RECEPTOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER SURGERY; CELL MIGRATION; CONTROLLED STUDY; GASTROINTESTINAL TRACT; HUMAN; HUMAN TISSUE; METASTASIS; PANCREAS CANCER; PANCREATIC DUCT ADENOCARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ADENOCARCINOMA; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; HEPATOCYTE GROWTH FACTOR; HUMANS; NEOPLASM INVASIVENESS; NEUROPEPTIDES; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, NEUROTRANSMITTER;

EID: 61849136239     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.11.028     Document Type: Article

References (51)

1. Minamino N., Kangawa K., and Matsuo H. Neuromedin U-8 and U-25: novel uterus stimulating and hypertensive peptides identified in porcine spinal cord. Biochem. Biophys. Res. Commun. 130 (1985) 1078-1085
2. Minamino N., Sudoh T., Kangawa K., and Matsuo H. Neuromedins: novel smooth-muscle stimulating peptides identified in porcine spinal cord. Peptides 6 Suppl. 3 (1985) 245-248
3. Austin C., Lo G., Nandha K.A., Meleagros L., and Bloom S.R. Cloning and characterization of the cDNA encoding the human neuromedin U (NmU) precursor: NmU expression in the human gastrointestinal tract. J. Mol. Endocrinol. 14 (1995) 157-169
4. Austin C., Oka M., Nandha K.A., Legon S., Khandan-Nia N., Lo G., and Bloom S.R. Distribution and developmental pattern of neuromedin U expression in the rat gastrointestinal tract. J. Mol. Endocrinol. 12 (1994) 257-263
5. Ballesta J., Carlei F., Bishop A.E., Steel J.H., Gibson S.J., Fahey M., Hennessey R., Domin J., Bloom S.R., and Polak J.M. Occurrence and developmental pattern of neuromedin U-immunoreactive nerves in the gastrointestinal tract and brain of the rat. Neuroscience 25 (1988) 797-816
6. Domin J., Ghatei M.A., Chohan P., and Bloom S.R. Neuromedin U-a study of its distribution in the rat. Peptides 8 (1987) 779-784
7. Honzawa M., Sudoh T., Minamino N., Kangawa K., and Matsuo H. Neuromedin U-like immunoreactivity in rat intestine: regional distribution and immunohistochemical study. Neuropeptides 15 (1990) 1-9
8. Howard A.D., Wang R., Pong S.S., Mellin T.N., Strack A., Guan X.M., Zeng Z., Williams Jr. D.L., Feighner S.D., Nunes C.N., Murphy B., Stair J.N., Yu H., Jiang Q., Clements M.K., Tan C.P., McKee K.K., Hreniuk D.L., McDonald T.P., Lynch K.R., Evans J.F., Austin C.P., Caskey C.T., Van der Ploeg L.H., and Liu Q. Identification of receptors for neuromedin U and its role in feeding. Nature 406 (2000) 70-74
9. Raddatz R., Wilson A.E., Artymyshyn R., Bonini J.A., Borowsky B., Boteju L.W., Zhou S., Kouranova E.V., Nagorny R., Guevarra M.S., Dai M., Lerman G.S., Vaysse P.J., Branchek T.A., Gerald C., Forray C., and Adham N. Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system. J. Biol. Chem. 275 (2000) 32452-32459
10. Shan L., Qiao X., Crona J.H., Behan J., Wang S., Laz T., Bayne M., Gustafson E.L., Monsma Jr. F.J., and Hedrick J.A. Identification of a novel neuromedin U receptor subtype expressed in the central nervous system. J. Biol. Chem. 275 (2000) 39482-39486
11. Brighton P.J., Szekeres P.G., Wise A., and Willars G.B. Signaling and ligand binding by recombinant neuromedin U receptors: evidence for dual coupling to Galphaq/11 and Galphai and an irreversible ligand-receptor interaction. Mol. Pharmacol. 66 (2004) 1544-1556
12. Hedrick J.A., Morse K., Shan L., Qiao X., Pang L., Wang S., Laz T., Gustafson E.L., Bayne M., and Monsma Jr. F.J. Identification of a human gastrointestinal tract and immune system receptor for the peptide neuromedin U. Mol. Pharmacol. 58 (2000) 870-875
13. Westfall T.D., McCafferty G.P., Pullen M., Gruver S., Sulpizio A.C., Aiyar V.N., Disa J., Contino L.C., Mannan I.J., and Hieble J.P. Characterization of neuromedin U effects in canine smooth muscle. J. Pharmacol. Exp. Ther. 301 (2002) 987-992
14. Gardiner S.M., Compton A.M., and Bennett T. Regional hemodynamic effects of endothelin-2 and sarafotoxin-S6b in conscious rats. Am. J. Physiol. 258 (1990) R912-R917
15. Sumi S., Inoue K., Kogire M., Doi R., Takaori K., Suzuki T., Yajima H., and Tobe T. Effect of synthetic neuromedin U-8 and U-25, novel peptides identified in porcine spinal cord, on splanchnic circulation in dogs. Life Sci. 41 (1987) 1585-1590
16. Chu C., Jin Q., Kunitake T., Kato K., Nabekura T., Nakazato M., Kangawa K., and Kannan H. Cardiovascular actions of central neuromedin U in conscious rats. Regul. Pept. 105 (2002) 29-34
17. Hanada R., Nakazato M., Murakami N., Sakihara S., Yoshimatsu H., Toshinai K., Hanada T., Suda T., Kangawa K., Matsukura S., and Sakata T. A role for neuromedin U in stress response. Biochem. Biophys. Res. Commun. 289 (2001) 225-228
18. Wren A.M., Small C.J., Abbott C.R., Jethwa P.H., Kennedy A.R., Murphy K.G., Stanley S.A., Zollner A.N., Ghatei M.A., and Bloom S.R. Hypothalamic actions of neuromedin U. Endocrinology 143 (2002) 4227-4234
19. Cao C.Q., Yu X.H., Dray A., Filosa A., and Perkins M.N. A pro-nociceptive role of neuromedin U in adult mice. Pain 104 (2003) 609-616
20. Shetzline S.E., Rallapalli R., Dowd K.J., Zou S., Nakata Y., Swider C.R., Kalota A., Choi J.K., and Gewirtz A.M. Neuromedin U: a Myb-regulated autocrine growth factor for human myeloid leukemias. Blood 104 (2004) 1833-1840
21. Euer N.I., Kaul S., Deissler H., Mobus V.J., Zeillinger R., and Weidle U.H. Identification of L1CAM, Jagged2 and neuromedin U as ovarian cancer-associated antigens. Oncol. Rep. 13 (2005) 375-387
22. Takahashi K., Furukawa C., Takano A., Ishikawa N., Kato T., Hayama S., Suzuki C., Yasui W., Inai K., Sone S., Ito T., Nishimura H., Tsuchiya E., Nakamura Y., and Daigo Y. The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res. 66 (2006) 9408-9419
23. Alevizos I., Mahadevappa M., Zhang X., Ohyama H., Kohno Y., Posner M., Gallagher G.T., Varvares M., Cohen D., Kim D., Kent R., Donoff R.B., Todd R., Yung C.M., Warrington J.A., and Wong D.T. Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis. Oncogene 20 (2001) 6196-6204
24. Yamashita K., Upadhyay S., Osada M., Hoque M.O., Xiao Y., Mori M., Sato F., Meltzer S.J., and Sidransky D. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2 (2002) 485-495
25. Nakamura T., Nishizawa T., Hagiya M., Seki T., Shimonishi M., Sugimura A., Tashiro K., and Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature 342 (1989) 440-443
26. Stoker M., Gherardi E., Perryman M., and Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327 (1987) 239-242
27. Weidner K.M., Arakaki N., Hartmann G., Vandekerckhove J., Weingart S., Rieder H., Fonatsch C., Tsubouchi H., Hishida T., Daikuhara Y., et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc. Natl. Acad. Sci. USA 88 (1991) 7001-7005
28. Birchmeier C., and Gherardi E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 8 (1998) 404-410
29. Zhang Y.W., and Vande Woude G.F. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J. Cell. Biochem. 88 (2003) 408-417
30. Gherardi E., Sharpe M., and Lane K. Properties and structure-function relationship of HGF-SF. Exs 65 (1993) 31-48
31. Gherardi E., Sharpe M., Lane K., Sirulnik A., and Stoker M. Hepatocyte growth factor/scatter factor (HGF/SF), the c-met receptor and the behaviour of epithelial cells. Symp. Soc. Exp. Biol. 47 (1993) 163-181
32. Medico E., Mongiovi A.M., Huff J., Jelinek M.A., Follenzi A., Gaudino G., Parsons J.T., and Comoglio P.M. The tyrosine kinase receptors Ron and Sea control "scattering" and morphogenesis of liver progenitor cells in vitro. Mol. Biol. Cell 7 (1996) 495-504
33. Ebert M., Yokoyama M., Friess H., Buchler M.W., and Korc M. Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res. 54 (1994) 5775-5778
34. Furukawa T., Duguid W.P., Kobari M., Matsuno S., and Tsao M.S. Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. Am. J. Pathol. 147 (1995) 889-895
35. Erkan M., Kleeff J., Esposito I., Giese T., Ketterer K., Buchler M.W., Giese N.A., and Friess H. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 24 (2005) 4421-4432
36. Michalski C.W., Laukert T., Sauliunaite D., Pacher P., Bergmann F., Agarwal N., Su Y., Giese T., Giese N.A., Batkai S., Friess H., and Kuner R. Cannabinoids ameliorate pain and reduce disease pathology in cerulein-induced acute pancreatitis. Gastroenterology 132 (2007) 1968-1978
37. Ketterer K., Rao S., Friess H., Weiss J., Buchler M.W., and Korc M. Reverse transcription-PCR analysis of laser-captured cells points to potential paracrine and autocrine actions of neurotrophins in pancreatic cancer. Clin. Cancer. Res. 9 (2003) 5127-5136
38. Michalski C.W., Shi X., Reiser C., Fachinger P., Zimmermann A., Buchler M.W., Di Sebastiano P., and Friess H. Neurokinin-2 receptor levels correlate with intensity, frequency, and duration of pain in chronic pancreatitis. Ann. Surg. 246 (2007) 786-793
39. Michalski C.W., Autschbach F., Selvaggi F., Shi X., Di Mola F.F., Roggo A., Muller M.W., Di Sebastiano P., Buchler M.W., Giese T., and Friess H. Increase in substance P precursor mRNA in noninflamed small-bowel sections in patients with Crohn's disease. Am. J. Surg. 193 (2007) 476-481
40. Brandt R., Grutzmann R., Bauer A., Jesnowski R., Ringel J., Lohr M., Pilarsky C., and Hoheisel J.D. DNA microarray analysis of pancreatic malignancies. Pancreatology 4 (2004) 587-597
41. Fellenberg K., Hauser N.C., Brors B., Hoheisel J.D., and Vingron M. Microarray data warehouse allowing for inclusion of experiment annotations in statistical analysis. Bioinformatics 18 (2002) 423-433
42. Fellenberg K., Hauser N.C., Brors B., Neutzner A., Hoheisel J.D., and Vingron M. Correspondence analysis applied to microarray data. Proc. Natl. Acad. Sci. USA 98 (2001) 10781-10786
43. Beissbarth T., Fellenberg K., Brors B., Arribas-Prat R., Boer J., Hauser N.C., Scheideler M., Hoheisel J.D., Schutz G., Poustka A., and Vingron M. Processing and quality control of DNA array hybridization data. Bioinformatics 16 (2000) 1014-1022
44. Fellenberg K., Busold C.H., Witt O., Bauer A., Beckmann B., Hauser N.C., Frohme M., Winter S., Dippon J., and Hoheisel J.D. Systematic interpretation of microarray data using experiment annotations. BMC Genomics 7 (2006) 319
45. Michalski C.W., Maier M., Erkan M., Sauliunaite D., Bergmann F., Pacher P., Batkai S., Giese N.A., Giese T., Friess H., and Kleeff J. Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells. PLoS ONE 3 (2008) e1701
46. Tokumaru Y., Yamashita K., Osada M., Nomoto S., Sun D.I., Xiao Y., Hoque M.O., Westra W.H., Califano J.A., and Sidransky D. Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res. 64 (2004) 5982-5987
47. Wu Y., McRoberts K., Berr S.S., Frierson Jr. H.F., Conaway M., and Theodorescu D. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. Oncogene 26 (2007) 765-773
48. Moriyama M., Fukuyama S., Inoue H., Matsumoto T., Sato T., Tanaka K., Kinjyo I., Kano T., Yoshimura A., and Kojima M. The neuropeptide neuromedin U activates eosinophils and is involved in allergen-induced eosinophilia. Am. J. Physiol. Lung Cell. Mol. Physiol. 290 (2006) L971-L977
49. Moriyama M., Matsukawa A., Kudoh S., Takahashi T., Sato T., Kano T., Yoshimura A., and Kojima M. The neuropeptide neuromedin U promotes IL-6 production from macrophages and endotoxin shock. Biochem. Biophys. Res. Commun. 341 (2006) 1149-1154
50. Moriyama M., Sato T., Inoue H., Fukuyama S., Teranishi H., Kangawa K., Kano T., Yoshimura A., and Kojima M. The neuropeptide neuromedin U promotes inflammation by direct activation of mast cells. J. Exp. Med. 202 (2005) 217-224
51. Dass N.B., Bassil A.K., North-Laidler V.J., Morrow R., Aziz E., Tuladhar B.R., and Sanger G.J. Neuromedin U can exert colon-specific, enteric nerve-mediated prokinetic activity, via a pathway involving NMU1 receptor activation. Brit. J. Pharmacol. 150 (2007) 502-508